Efzofitimod Sales Forecast, and Market Size Analysis – 2034
Description
Key Factors Driving Efzofitimod Growth
1. First-in-Class Mechanism Targeting Neuropilin-2 (NRP2)
Efzofitimod is a first-in-class immunomodulator that selectively binds to neuropilin-2 (NRP2), a receptor upregulated on activated immune cells in inflammatory diseases like sarcoidosis.
It modulates innate and adaptive immune responses, particularly macrophage-driven inflammation.
Unlike corticosteroids, it targets underlying disease biology rather than broad immunosuppression.
Strong differentiation supports premium positioning and potential adoption in steroid-refractory patients
Platform potential across multiple ILDs increases long-term value
2. High Unmet Need in Pulmonary Sarcoidosis
Pulmonary sarcoidosis is a chronic granulomatous disease with limited approved therapies, where corticosteroids remain the standard of care despite toxicity concerns.
Long-term steroid use is associated with significant adverse effects, creating demand for steroid-sparing agents.
If approved, efzofitimod could become one of the first novel therapies in decades, addressing a clear unmet need
Drives rapid uptake in specialist pulmonary centers
3. Large, Global Phase III Program Validating Commercial Potential
The EFZO-FIT Phase III trial enrolled 268 patients across 85 sites in 9 countries, the largest interventional sarcoidosis study conducted.
Demonstrates global clinical interest and scalability
Builds strong physician awareness and KOL engagement pre-launch
4. Encouraging Secondary Clinical Outcomes Despite Primary Endpoint Miss
Phase III results (2025) showed:
5. Expansion Potential into Multiple Interstitial Lung Diseases (ILDs)
Mechanism suggests applicability beyond sarcoidosis, including:
Transforms efzofitimod from a single-asset drug to a platform asset
Expands total addressable market significantly beyond sarcoidosis
Efzofitimod Recent Developments
In February 2023, aTyr Pharma announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase III study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD). This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.
“Efzofitimod Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Efzofitimod for potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis in the 7MM. A detailed picture of Efzofitimod’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Efzofitimod for potential indications. The Efzofitimod market report provides insights about Efzofitimod’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Efzofitimod performance, future market assessments inclusive of the Efzofitimod market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Efzofitimod sales forecasts, along with factors driving its market.
Efzofitimod Drug Summary
Efzofitimod is an investigational, first-in-class immunomodulatory biologic derived from a splice variant of histidyl-tRNA synthetase, being developed primarily for the treatment of interstitial lung diseases, particularly pulmonary sarcoidosis. It selectively binds to neuropilin-2 (NRP2), a receptor expressed on activated immune cells, thereby modulating inflammatory pathways and reducing granulomatous inflammation without broadly suppressing the immune system. Administered via intravenous infusion, efzofitimod has demonstrated promising results in early-phase clinical trials, including improvements in lung function and reductions in corticosteroid use among sarcoidosis patients, supporting its potential as a steroid-sparing therapy. The drug has generally shown a favorable safety and tolerability profile, though it remains under clinical investigation and has not yet received regulatory approval. The report provides Efzofitimod’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Efzofitimod Market Report
The report provides insights into:
A comprehensive product overview including the Efzofitimod MoA, description, dosage and administration, research and development activities in potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis.
Elaborated details on Efzofitimod regulatory milestones and other development activities have been provided in Efzofitimod market report.
The report also highlights Efzofitimod‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
The Efzofitimod market report also covers the patents information, generic entry and impact on cost cut.
The Efzofitimod market report contains current and forecasted Efzofitimod sales for potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Efzofitimod market report also features the SWOT analysis with analyst views for Efzofitimod in potential indications.
Methodology
The Efzofitimod market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Efzofitimod Analytical Perspective by DelveInsight
In-depth Efzofitimod Market Assessment
This Efzofitimod sales market forecast report provides a detailed market assessment of Efzofitimod for potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Efzofitimod sales data uptil 2034.
Efzofitimod Clinical Assessment
The Efzofitimod market report provides the clinical trials information of Efzofitimod for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Efzofitimod Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Efzofitimod Market Potential & Revenue Forecast
Projected market size for the Efzofitimod and its key indications
Estimated Efzofitimod sales potential (Efzofitimod peak sales forecasts)
Efzofitimod Pricing strategies and reimbursement landscape
Efzofitimod Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Efzofitimod Market positioning compared to existing treatments
Efzofitimod Strengths & weaknesses relative to competitors
Efzofitimod Regulatory & Commercial Milestones
Efzofitimod Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Efzofitimod Clinical Differentiation
Efzofitimod Efficacy & safety advantages over existing drugs
Efzofitimod Unique selling points
Efzofitimod Market Report Highlights
In the coming years, the Efzofitimod market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Efzofitimod companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Efzofitimod’s dominance.
Other emerging products for Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis are expected to give tough market competition to Efzofitimod and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Efzofitimod in potential indications.
Analyse Efzofitimod cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Efzofitimod sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Efzofitimod in potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Efzofitimod? How strong is Efzofitimod’s clinical and commercial performance?
What is Efzofitimod’s clinical trial status in each individual indications such as Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Efzofitimod Manufacturers?
What are the key designations that have been granted to Efzofitimod for potential indications? How are they going to impact Efzofitimod’s penetration in various geographies?
What is the current and forecasted Efzofitimod market scenario for potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Efzofitimod in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Efzofitimod for potential indications?
Which are the late-stage emerging therapies under development for the treatment of potential indications?
How cost-effective is Efzofitimod? What is the duration of therapy and what are the geographical variations in cost per patient?
1. First-in-Class Mechanism Targeting Neuropilin-2 (NRP2)
Efzofitimod is a first-in-class immunomodulator that selectively binds to neuropilin-2 (NRP2), a receptor upregulated on activated immune cells in inflammatory diseases like sarcoidosis.
It modulates innate and adaptive immune responses, particularly macrophage-driven inflammation.
Unlike corticosteroids, it targets underlying disease biology rather than broad immunosuppression.
Strong differentiation supports premium positioning and potential adoption in steroid-refractory patients
Platform potential across multiple ILDs increases long-term value
2. High Unmet Need in Pulmonary Sarcoidosis
Pulmonary sarcoidosis is a chronic granulomatous disease with limited approved therapies, where corticosteroids remain the standard of care despite toxicity concerns.
Long-term steroid use is associated with significant adverse effects, creating demand for steroid-sparing agents.
If approved, efzofitimod could become one of the first novel therapies in decades, addressing a clear unmet need
Drives rapid uptake in specialist pulmonary centers
3. Large, Global Phase III Program Validating Commercial Potential
The EFZO-FIT Phase III trial enrolled 268 patients across 85 sites in 9 countries, the largest interventional sarcoidosis study conducted.
Demonstrates global clinical interest and scalability
Builds strong physician awareness and KOL engagement pre-launch
4. Encouraging Secondary Clinical Outcomes Despite Primary Endpoint Miss
Phase III results (2025) showed:
- 52.6% steroid withdrawal vs 40.2% placebo
- Significant improvement in KSQ-Lung quality-of-life score (p=0.0479)
5. Expansion Potential into Multiple Interstitial Lung Diseases (ILDs)
Mechanism suggests applicability beyond sarcoidosis, including:
- Systemic sclerosis-associated ILD (SSc-ILD) (ongoing studies)
Transforms efzofitimod from a single-asset drug to a platform asset
Expands total addressable market significantly beyond sarcoidosis
Efzofitimod Recent Developments
In February 2023, aTyr Pharma announced that its partner Kyorin Pharmaceutical Co., Ltd. (Kyorin), a wholly owned subsidiary of Kyorin Holdings, Inc., dosed the first patient in Japan in EFZO-FIT™, a global pivotal Phase III study to evaluate the efficacy and safety of the Company’s lead therapeutic candidate, efzofitimod, in patients with pulmonary sarcoidosis, a major form of interstitial lung disease (ILD). This achievement has triggered a $10 million milestone payment by Kyorin to aTyr pursuant to a collaboration and license agreement between the Company and Kyorin.
“Efzofitimod Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Efzofitimod for potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis in the 7MM. A detailed picture of Efzofitimod’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Efzofitimod for potential indications. The Efzofitimod market report provides insights about Efzofitimod’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Efzofitimod performance, future market assessments inclusive of the Efzofitimod market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Efzofitimod sales forecasts, along with factors driving its market.
Efzofitimod Drug Summary
Efzofitimod is an investigational, first-in-class immunomodulatory biologic derived from a splice variant of histidyl-tRNA synthetase, being developed primarily for the treatment of interstitial lung diseases, particularly pulmonary sarcoidosis. It selectively binds to neuropilin-2 (NRP2), a receptor expressed on activated immune cells, thereby modulating inflammatory pathways and reducing granulomatous inflammation without broadly suppressing the immune system. Administered via intravenous infusion, efzofitimod has demonstrated promising results in early-phase clinical trials, including improvements in lung function and reductions in corticosteroid use among sarcoidosis patients, supporting its potential as a steroid-sparing therapy. The drug has generally shown a favorable safety and tolerability profile, though it remains under clinical investigation and has not yet received regulatory approval. The report provides Efzofitimod’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Efzofitimod Market Report
The report provides insights into:
A comprehensive product overview including the Efzofitimod MoA, description, dosage and administration, research and development activities in potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis.
Elaborated details on Efzofitimod regulatory milestones and other development activities have been provided in Efzofitimod market report.
The report also highlights Efzofitimod‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
The Efzofitimod market report also covers the patents information, generic entry and impact on cost cut.
The Efzofitimod market report contains current and forecasted Efzofitimod sales for potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Efzofitimod market report also features the SWOT analysis with analyst views for Efzofitimod in potential indications.
Methodology
The Efzofitimod market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Efzofitimod Analytical Perspective by DelveInsight
In-depth Efzofitimod Market Assessment
This Efzofitimod sales market forecast report provides a detailed market assessment of Efzofitimod for potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Efzofitimod sales data uptil 2034.
Efzofitimod Clinical Assessment
The Efzofitimod market report provides the clinical trials information of Efzofitimod for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Efzofitimod Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Efzofitimod Market Potential & Revenue Forecast
Projected market size for the Efzofitimod and its key indications
Estimated Efzofitimod sales potential (Efzofitimod peak sales forecasts)
Efzofitimod Pricing strategies and reimbursement landscape
Efzofitimod Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Efzofitimod Market positioning compared to existing treatments
Efzofitimod Strengths & weaknesses relative to competitors
Efzofitimod Regulatory & Commercial Milestones
Efzofitimod Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Efzofitimod Clinical Differentiation
Efzofitimod Efficacy & safety advantages over existing drugs
Efzofitimod Unique selling points
Efzofitimod Market Report Highlights
In the coming years, the Efzofitimod market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Efzofitimod companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Efzofitimod’s dominance.
Other emerging products for Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis are expected to give tough market competition to Efzofitimod and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Efzofitimod in potential indications.
Analyse Efzofitimod cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Efzofitimod sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Efzofitimod in potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Efzofitimod? How strong is Efzofitimod’s clinical and commercial performance?
What is Efzofitimod’s clinical trial status in each individual indications such as Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Efzofitimod Manufacturers?
What are the key designations that have been granted to Efzofitimod for potential indications? How are they going to impact Efzofitimod’s penetration in various geographies?
What is the current and forecasted Efzofitimod market scenario for potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Efzofitimod in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Efzofitimod for potential indications?
Which are the late-stage emerging therapies under development for the treatment of potential indications?
How cost-effective is Efzofitimod? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
30 Pages
- 1. Report Introduction
- 2. Efzofitimod Overview in potential indication like Pulmonary sarcoidosis, COVID-19 pneumonia, Interstitial lung diseases and Rheumatoid arthritis
- 2.1. Product Detail
- 2.2. Efzofitimod Clinical Development
- 2.2.1. Efzofitimod Clinical studies
- 2.2.2. Efzofitimod Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
- 3. Efzofitimod Competitive Landscape (Marketed Therapies)
- 4. Competitive Landscape (Late-stage Emerging Efzofitimod Therapies)
- 5. Efzofitimod Market Assessment
- 5.1. Efzofitimod Market Outlook in potential indications
- 5.2. 7MM Analysis
- 5.2.1. Efzofitimod Market Size in the 7MM for potential indications
- 5.3. Country-wise Market Analysis
- 5.3.1. Efzofitimod Market Size in the United States for potential indications
- 5.3.2. Efzofitimod Market Size in Germany for potential indications
- 5.3.3. Efzofitimod Market Size in France for potential indications
- 5.3.4. Efzofitimod Market Size in Italy for potential indications
- 5.3.5. Efzofitimod Market Size in Spain for potential indications
- 5.3.6. Efzofitimod Market Size in the United Kingdom for potential indications
- 5.3.7. Efzofitimod Market Size in Japan for potential indications
- 6. Efzofitimod SWOT Analysis
- 7. Analysts’ Views
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
- 12. Report Purchase Options
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
